AEON Biopharma, Inc. (NASDAQ:AEON – Free Report) – Equities research analysts at HC Wainwright issued their FY2026 earnings per share estimates for AEON Biopharma in a research report issued to clients and investors on Friday, August 14th. HC Wainwright analyst D. Tsao expects that the company will post earnings of ($0.56) per share for the year. HC Wainwright currently has a “Buy” rating and a $1.20 price target on the stock. The consensus estimate for AEON Biopharma’s current full-year earnings is ($0.77) per share. HC Wainwright also issued estimates for AEON Biopharma’s FY2027 earnings at ($0.25) EPS.
Several other research firms have also recently commented on AEON. Lake Street Capital assumed coverage on shares of AEON Biopharma in a research note on Thursday, July 30th. They set a “buy” rating and a $1.00 price target on the stock. Zacks Research upgraded shares of AEON Biopharma to a “hold” rating in a research report on Wednesday, May 27th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $1.10.
AEON Biopharma Trading Down 7.1%
Shares of NASDAQ AEON opened at $0.26 on Tuesday. AEON Biopharma has a 1-year low of $0.22 and a 1-year high of $1.45. The company has a market cap of $6.46 million, a PE ratio of 1.42 and a beta of 0.65. The company has a 50-day moving average of $0.47 and a two-hundred day moving average of $0.81.
Institutional Inflows and Outflows
An institutional investor recently raised its stake in AEON Biopharma stock. XTX Topco Ltd increased its holdings in shares of AEON Biopharma, Inc. (NASDAQ:AEON – Free Report) by 251.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 56,852 shares of the company’s stock after buying an additional 40,690 shares during the period. XTX Topco Ltd owned 0.48% of AEON Biopharma worth $63,000 at the end of the most recent quarter. Institutional investors own 22.78% of the company’s stock.
AEON Biopharma Company Profile
AEON Biopharma, Inc, formerly Allied Energy Corp., is a clinical‐stage biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases. The company applies enzyme replacement and gene therapy platforms to address unmet medical needs in central nervous system and metabolic disorders. Its lead program, AES-103, is being developed as an enzyme replacement therapy for Crigler-Najjar syndrome, a hereditary condition characterized by high levels of unconjugated bilirubin.
Beyond AES-103, AEON Biopharma is advancing AES-201 for X-linked adrenoleukodystrophy (X-ALD), a progressive neurological disorder, and AES-104 for post–COVID-19 conditions, commonly referred to as “long COVID.” These programs are in preclinical or early clinical stages, with ongoing efforts to optimize delivery, evaluate safety profiles and establish proof of concept.
Featured Stories
- Five stocks we like better than AEON Biopharma
- Moonshot to Money: Intuitive Machines Lands $600M Defense Win
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
Receive News & Ratings for AEON Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEON Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
